Financials Prediction Markets

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)
Yes
No
$75 vol
FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)
Yes
No
$434 vol
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
Yes
No
$4,230 vol
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
Yes
No
$944 vol
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading